Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast15
NCT05950945Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05950945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950945.